Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors.

By successful uncoupling of the PD-1/PD-L1 axis, we provide further evidence for the safe and successful application of immunotherapies to combat dMMR-driven malignancies that warrants further investigation.